Randomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-006-9306-9 ◽

2006 ◽

Vol 101 (3) ◽

pp. 355-365 ◽

Cited By ~ 92

Author(s):

Giampietro Gasparini ◽

Massimo Gion ◽

Luigi Mariani ◽

Paola Papaldo ◽

Diana Crivellari ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Weekly Paclitaxel ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii ◽

Her 2

5001 CIRG/TORI 010: first analysis of a randomized phase II trial of motesanib plus weekly paclitaxel (P) as first line therapy in HER2-negative metastatic breast cancer (MBC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70893-6 ◽

2009 ◽

Vol 7 (2) ◽

pp. 260

Author(s):

M. Martin ◽

S. Hurvitz ◽

J. Kennedy ◽

J. Forbes ◽

H. Roché ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Weekly Paclitaxel ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group

BMC Cancer ◽

10.1186/s12885-020-07047-1 ◽

2020 ◽

Vol 20 (1) ◽

Cited By ~ 1

Author(s):

Kenro Hirata ◽

Yasuo Hamamoto ◽

Masahiko Ando ◽

Chiyo K. Imamura ◽

Kenichi Yoshimura ◽

...

Keyword(s):

Gastric Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Peritoneal Dissemination ◽

Oncology Group ◽

First Line ◽

The West ◽

First Line Therapy ◽

Line Therapy ◽

Select Trial

Safety analysis of weekly paclitaxel plus S-1 versus paclitaxel plus 5-fluorouracil/calcium folinate as first-line therapy in advanced gastric cancer: a multicenter open random phase II trial

Journal of Chemotherapy ◽

10.1179/1973947812y.0000000057 ◽

2013 ◽

Vol 25 (1) ◽

pp. 56-59

Author(s):

Ting Deng ◽

Nong Xu ◽

Jian-Ping Xiong ◽

Zhao Yan ◽

Zhi-Xiang Zhuang ◽

...

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Random Phase ◽

Calcium Folinate ◽

Weekly Paclitaxel ◽

First Line ◽

First Line Therapy ◽

Line Therapy

CIRG/TORI 010: 10-Month Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel as First Line Therapy in HER2-Negative Metastatic Breast Cancer (MBC).

10.1158/0008-5472.sabcs-09-47 ◽

2009 ◽

Cited By ~ 3

Author(s):

J. Mackey ◽

S. Hurvitz ◽

J. Crown ◽

J. Forbes ◽

H. Roché ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Weekly Paclitaxel ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

740 POSTER Fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP) as a first line therapy in patients with advanced gastric cancer —interim analysis of a multicenter, randomized phase II trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)81035-3 ◽

2005 ◽

Vol 3 (2) ◽

pp. 211-212

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Phase Ii ◽

Interim Analysis ◽

Phase Ii Trial ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

P1-14-01: Randomized Phase II Trial of Weekly vs. q 2-Weekly vs. q 3-Weekly Nanoparticle Albumin-Bound Paclitaxel with Bevacizumab as First-Line Therapy for Metastatic Breast Cancer.

10.1158/0008-5472.sabcs11-p1-14-01 ◽

2011 ◽

Author(s):

AD Seidman ◽

AK Conlin ◽

A Bach ◽

A Forero-Torres ◽

G Wright ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

LBA19 GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2– endocrine sensitive advanced breast cancer (ABC)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2247 ◽

2020 ◽

Vol 31 ◽

pp. S1151

Author(s):

J. Albanell ◽

M.T.M. Martinez ◽

M. Ramos ◽

M.O.' Connor ◽

L. De la Cruz-Merino ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

295 Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(03)90328-4 ◽

2003 ◽

Vol 1 (5) ◽

pp. S90-S91 ◽

Cited By ~ 16

Author(s):

A. Grothey ◽

K. Jordan ◽

O. Kellner ◽

C. Constantin ◽

G. Dietrich ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Advanced Colorectal Cancer ◽

Phase Ii Trial ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial

Annals of Oncology ◽

10.1093/annonc/mdg199 ◽

2003 ◽

Vol 14 (5) ◽

pp. 699-703 ◽

Cited By ~ 5

Author(s):

I. Elomaa ◽

H. Joensuu ◽

C. Blomqvist

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽